|Articles|May 4, 2006

2006 Conference Statistics

Author(s)BioPharm International Editors

Data from recent Biotech/Pharmaceutical Industry Conference/Events

To view a PDF of this article from the BioPharm International archives, click this link

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

Concept image of the six most common questions | Image Credit: © RTimages - stock.adobe.com

Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program

ByChristopher Cole

November 19th 2025

Transparent glass vial with clear liquid on a shadowed surface | Image credit: © Artyom - © Artyom - stock.adobe.com

Implications of the First Liquid IV Infliximab Biosimilar

ByFeliza Mirasol

November 18th 2025

Motor neuron connecting to muscle fiber, 3D illustration | Image credit: © Julian - © Julian - stock.adobe.com

What a High-Dose Nusinersen Option Means for Future SMA Care

ByFeliza Mirasol

November 17th 2025

Data technology background. Big data visualization. Flow of data. Information code. Background in a matrix style. 4k rendering. | Image Credit: © Dmitry - stock.adobe.com

Weighing Digitalization Efficiency Against Upskilling and Quality Concerns

ByPatrick Lavery

November 17th 2025

E&L Challenges in Biologics, Part Two

BySusan Haigney,Feliza Mirasol

November 14th 2025

2006 Conference Statistics

Newsletter

Related Content

Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program

Implications of the First Liquid IV Infliximab Biosimilar

What a High-Dose Nusinersen Option Means for Future SMA Care

Weighing Digitalization Efficiency Against Upskilling and Quality Concerns

E&L Challenges in Biologics, Part Two

Trending on BioPharm International

Implications of the First Liquid IV Infliximab Biosimilar

Integrated Services for the Whole Drug Development Pathway

Risks, Resource Strain, and Trade-Offs in FDA’s CNPV Pilot Program